LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway

Figure 4 LB100 downregulates the protein levels of lipogenesis genes, upregulates the expression of proteins involved in fatty acid β-oxidation, and activates the AMPK/Sirt1 signaling pathway in L02 cells. A: Protein expression levels of phosphorylated AMP-activated protein kinase α, AMPKα and Sirtuin 1 were detected by western blot analysis; B: Western blot analysis of proteins involved in lipid synthesis, such as fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), sterol regulatory element-binding protein 1 (SREBP1), and stearoyl-CoA desaturase-1 (SCD1); C: Proteins involved in fatty acid β-oxidation, such as peroxisome proliferator-activated receptor α, peroxisome proliferator-activated receptor gamma coactivator-1α, carnitine palmitoyltransferase 1α, uncoupling protein 2 and acyl-CoA oxidase 1; D: The mRNA levels of SREBP1 and its lipogenesis target genes, including FAS, ACC1 and SCD1, were determined using real-time PCR. Three independent experiments were analyzed, and the data are presented as the mean ± standard deviation. ^aP < 0.05, ^bP < 0.01 vs bovine serum albumin group; ^cP < 0.05, ^dP < 0.01 vs FFA group. P AMPK α: Phosphorylated AMP-activated protein kinase α; Sirt1: Sirtuin 1; FAS: Fatty acid synthase; ACC: Acetyl-CoA carboxylase; SREBP1: Sterol regulatory element-binding protein 1; SCD1: Stearoyl-CoA desaturase-1; PPARα: Peroxisome proliferator-activated receptor α; PGC1α: Peroxisome proliferator-activated receptor gamma coactivator-1α; CPT1α: Carnitine palmitoyltransferase 1α; UCP2: Uncoupling protein 2; ACOX1: Acyl-CoA oxidase 1; BSA: Bovine serum albumin; FFA: Free fatty acid.